BUSINESS
Kyowa to Skip May Listing for Enbrel Biosimilar, Codeveloper YL Biologics to Move Ahead
Kyowa Pharmaceutical Industry has decided to take a pass on the upcoming May listing of its Enbrel (etanercept) biosimilar, one of the two follow-on biologics approved in March for Pfizer’s major rheumatoid arthritis drug. YL Biologics, a codeveloper who gained…
To read the full story
Related Article
- Japan’s 2nd Enbrel Biosimilar, Pfizer’s Herceptin Follow-On Get Listing
May 28, 2019
- Japan Clears Second Enbrel Biosimilars
March 27, 2019
BUSINESS
- Keytruda Holds Top Spot for 35th Straight Month in August: Encise
September 7, 2026
- Fuji Curbs Shipments of Simponi, Ranmark Biosimilars Soon after Launch
September 4, 2026
- Leqembi Subcutaneous Autoinjector Approved in China
September 4, 2026
- Nxera Gets US$8.6 Million OX2R Milestone from Centessa
September 4, 2026
- Top Medipal Shareholder Seeks CEO Ouster, Special Dividend
September 4, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





